Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Reneo Pharmaceuticals, Inc. (RPHM)
|
Add to portfolio |
|
|
|
| Price: |
$8.92
| | Metrics |
| OS: |
33.8
|
M
| |
|
|
| Market cap: |
$302
|
M
| |
|
|
|
Net cash:
|
$143
|
M
| |
$4.22
|
per share
|
|
EV:
|
$159
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($74.2)
|
M
| |
|
|
|
EBIT
|
($74.3)
|
M
| |
|
|
| EPS |
($1.89)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 37.7 | 0.0 | 28.2 | 0.0 | 13.1 |
| Revenue growth | | 33.9% | | | -100.0% | |
| Cost of goods sold | 0.0 | 53.8 | 0.0 | 39.8 | 0.0 | 15.5 |
| Gross profit | 0.0 | -16.1 | 0.0 | -11.6 | 0.0 | -2.4 |
| Gross margin | | -42.8% | | -41.4% | | -18.1% |
| Research and development | 37.7 | | 28.2 | | 15.9 | |
| General and administrative | 16.1 | 16.1 | 11.6 | 11.6 | 3.6 | 2.4 |
| EBIT | -53.8 | -53.8 | -39.8 | -39.8 | -19.6 | -15.5 |
| EBIT margin | | -142.8% | | -141.4% | | -118.1% |
| Pre-tax income | -52.0 | -52.0 | -39.8 | -39.8 | -19.5 | -12.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -52.0 | -52.0 | -39.8 | -39.8 | -19.5 | -12.4 |
| Net margin | | -137.8% | | -141.2% | | -95.0% |
| |
| Diluted EPS | ($2.12) | ($2.12) | ($2.19) | ($2.19) | ($9.60) | ($6.38) |
| Shares outstanding (diluted) | 24.5 | 24.5 | 18.1 | 18.1 | 2.0 | 1.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|